⌕
Nektar Therapeutics · NKTR · Nasdaq
Tenet — · insufficient data
Compare
$36.44−2.23%At close
$36.44−0.83 (−2.23%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Nektar Therapeutics (NKTR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 13, 2026 · 12:01 ET
NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down

Nektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.…

● Seeking AlphaNov 13, 2026 · 04:08 ET
Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript

Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript…

● MarketBeatNov 12, 2026 · 23:15 ET
What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call

Nektar Therapeutics NASDAQ: NKTR said it has initiated three Phase III studies of its experimental drug rezpegaldesleukin, or REZPEG, in atopic dermatitis and expects to begin a pivotal alopecia areata study in December,…

● Zacks Investment ResearchNov 12, 2026 · 19:06 ET
Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates

Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $2.16. This compares to a loss of $1.85 per share a year ago.…

● PRNewsWireNov 12, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Nektar Therapeutics Announces Third Quarter 2026 Financial Results

SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Cash and investments i…

● PRNewsWireNov 11, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Nektar Therapeutics to Participate in Two Investor Conferences in November

SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS Global Biopharma Conference Format: …

● Defense WorldNov 10, 2026 · 03:47 ET
CenterBook Partners LP Buys 26,346 Shares of Nektar Therapeutics $NKTR

CenterBook Partners LP bought a new position in Nektar Therapeutics (NASDAQ: NKTR) during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 26,346 shar…

● Seeking AlphaOct 30, 2026 · 12:18 ET
Nektar Therapeutics: Focus Returns To The Strengths Of The Company

NKTR's rezpegaldesleukin is now in phase 3 trials in atopic dermatitis, but there is additional data from the company's phase 2b REZOLVE-AD trial expected in Q1'27. The market focus has shifting back to atopic dermatitis…

● Zacks Investment ResearchOct 29, 2026 · 11:06 ET
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● PRNewsWireOct 27, 2026 · 18:00 ETCOMPANY'S OWN WORDS
Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-b…

● PRNewsWireOct 23, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified …

● Defense WorldOct 16, 2026 · 02:59 ET
Maze Therapeutics (NASDAQ:MAZE) vs. Nektar Therapeutics (NASDAQ:NKTR) Financial Analysis

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) and Maze Therapeutics (NASDAQ: MAZE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses ba…

● Zacks Investment ResearchOct 15, 2026 · 13:35 ET
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?

NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.…

● Defense WorldOct 3, 2026 · 04:41 ET
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Down – Here’s What Happened

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report)'s share price gapped down prior to trading on Thursday. The stock had previously closed at $60.54, but opened at $55.41. Nektar Therapeutics shares last traded at $50.…

● Seeking AlphaOct 2, 2026 · 16:08 ET
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More

Nektar Therapeutics is downgraded from Strong Buy to Hold due to safety concerns with REZPEG despite positive efficacy data. Phase 2b REZOLVE-AA study showed 63% off-treatment durability but 91.7% injection site reaction…

● Seeking AlphaOct 1, 2026 · 12:50 ET
Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript

Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript…

● MarketBeatOct 1, 2026 · 12:03 ET
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial

Nektar Therapeutics NASDAQ: NKTR presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to very severe alopecia a…

● BarronsOct 1, 2026 · 11:45 ET
Nektar Stock Sinks Despite Promising Hair Loss Treatment Data

Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug.…

● Schaeffers ResearchOct 1, 2026 · 11:44 ET
3 Biotech Stocks Put Traders Are Targeting Today

Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.…

● PRNewsWireOct 1, 2026 · 07:30 ET
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

Rezpegaldesleukin demonstrated durability and deepening of response through one year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechanism In alopecia area…

● Defense WorldOct 1, 2026 · 04:29 ET
Nektar Therapeutics (NASDAQ:NKTR) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen ratings firms that are covering the company, Marketbeat reports. One equities research anal…

● PRNewsWireSep 30, 2026 · 10:30 ET
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical response SAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ -- Nektar Therapeutics …

● PRNewsWireSep 28, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areata Company to host conference call with investors and analysts on Octo…

● PRNewsWireSep 25, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualifi…

● PRNewsWireAug 28, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified s…

● PRNewsWireAug 25, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as …

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.